Erschienen in:
01.08.2006 | Brief Report
In vitro antimicrobial activity of moxifloxacin against bacterial strains isolated from blood of neutropenic cancer patients
verfasst von:
A. Cometta, O. Marchetti, T. Calandra, J. Bille, W. V. Kern, S. Zinner, Infectious Diseases Group of the European Organization for Research and Treatment of Cancer (EORTC-IDG)
Erschienen in:
European Journal of Clinical Microbiology & Infectious Diseases
|
Ausgabe 8/2006
Einloggen, um Zugang zu erhalten
Excerpt
The use of fluoroquinolones has increased in neutropenic cancer patients over the past two decades. With respect to empiric treatment of fever in neutropenic patients, the poor activity of older quinolones against gram-positive cocci prompted physicians to add specific anti-gram-positive agents to provide better activity against streptococci, which are frequently isolated from these patients. The efficacy and safety of oral antibiotic regimens that include fluoroquinolones for the treatment of low-risk febrile neutropenic patients have been documented in two large studies [
1,
2]. The widespread use of fluoroquinolones as prophylactic agents in cancer patients has been associated with the occurrence of resistance in
E. coli and coagulase-negative staphylococci, organisms which are most often responsible for bacteremia in these patients [
3]. …
